Compare AbbVie Inc (ABBV) vs GeneDx Holdings Corp (WGS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
AbbVie Inc vs GeneDx Holdings Corp — how do they compare? AbbVie Inc trades at $248.69 (market cap $441.94B), while GeneDx Holdings Corp trades at $82.71 (market cap $2.44B). The key difference: AbbVie Inc is far larger — about 181.1× GeneDx Holdings Corp's market cap, and AbbVie Inc pays a 2.77% dividend while GeneDx Holdings Corp pays none. Which is the better fit depends on your goals.
| ABBV | WGS | |
|---|---|---|
Market Cap | $441.94B | $2.44B |
Sector | Health | Technology |
52-Week High | $263.58 | $167.51 |
52-Week Low | $197.38 | $34.51 |
Enterprise Value | $506.19B | $2.48B |
Dividend Yield | 2.77% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AbbVie (ABBV) trades at $248.40, up 0.2% with a bullish technical signal supported by moving averages. The company demonstrates strong revenue growth to $61.16B in 2025 and consistent earnings beats, though net margins have compressed. Recent positive Phase 2 data for ELAHERE in ovarian cancer and institutional buying activity highlight ongoing momentum. Valuation ratios appear elevated with a P/E of 70.65 and P/B of 245.29, reflecting premium pricing for its pharmaceutical pipeline.
Outlook remains positive with 70.7% analyst buy ratings and a $278.69 consensus target offering 12% upside. Key risks include patent expirations, regulatory challenges from drug pricing lawsuits, and high debt levels. The dividend aristocrat status and robust immunology portfolio position ABBV for sustained growth, though investors should monitor execution against lofty 2026 EPS expectations of $3.87 for Q3.
GeneDx Holdings Corp (WGS) trades at $82.07, up 5.38% in the past 24 hours, with technical indicators showing a bullish trend. The stock beat Q2 2026 EPS estimates but reported negative net income margins. Recent news highlights product expansion and institutional buying interest, though class-action lawsuits pose near-term sentiment risks.
Outlook is mixed: strong analyst buy ratings (90.9%) and a $79.25 consensus target suggest upside, but high valuation multiples and persistent losses require caution. Key risks include profitability challenges and legal overhangs, while revenue growth and market positioning offer long-term potential.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About AbbVie Inc
AbbVie is a pharmaceutical company with a strong exposure to immunology and oncology. The firm's top drug, Humira, represents close to half of the company's current profits. The company was spun off from Abbott in early 2013. The recent acquisition of Allergan adds several new drugs in aesthetics and women's health.
Read more on ABBV →About GeneDx Holdings Corp
GeneDx is a patient-centered health intelligence company that specializes in transforming healthcare through the application of genomics. It combines advanced technology with one of the world's largest rare disease genomic datasets to provide clinical-grade exome and genome sequencing, enabling precise and rapid diagnosis for patients with complex medical conditions.
Read more on WGS →
